Viking Therapeutics (VKTX) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 148.5% versus a loss of 27.7%. Over five years, XERS leads with a +682.0% price change compared with +360.4% for VKTX. Viking Therapeutics is the larger company by market cap ($3.16 billion vs $3.10 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VKTX | XERS |
|---|---|---|
| Share price | $24.77 | $16.97 |
| Market cap | $3.16B | $3.10B |
| 1-day change | -4.14% | +2.11% |
| YTD return | -29.59% | +116.18% |
| 1-year return | -27.70% | +148.46% |
| 5-year return | +360.41% | +682.03% |
| Forward P/E | — | 63.64 |
| EPS (TTM) | $-5.42 | $-0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | $-359.64M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $43.10 | $17.28 |
| 52-week low | $23.82 | $5.25 |
| Distance from 52-week high | -42.53% | -1.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +284.82% | +1.89% |
| Average volume | 5.31M | 2.86M |
| Shares outstanding | 127.52M | 182.70M |
| Employees | 74 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed VKTX by 176.2 percentage points over the past year.
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
VKTX vs XERS FAQ
Which is bigger, Viking Therapeutics or Xeris Biopharma?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.16B compared with $3.10B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, VKTX or XERS?
XERS returned +148.46% over the past 12 months, compared with -27.70% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Viking Therapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.